Novartis AG Receives Approval for Pluvicto and Appoints New Chief Legal Officer

Novartis AG, a Swiss pharmaceutical company, has received approval for its radiopharmaceutical medication Pluvicto from the US market. The approval allows Pluvicto to be used for an additional indication, expanding its commercial potential.

• The approval is a significant milestone for Novartis, marking a major development in the company’s product portfolio.
• The additional indication for Pluvicto is expected to increase the medication’s market presence in the US.

Appointment of New Chief Legal Officer

Novartis AG has announced the appointment of Karen Hale as Chief Legal and Compliance Officer, effective immediately. This appointment replaces Klaus Moosmayer, who has stepped down from the Executive Committee.

• Karen Hale brings extensive experience in the pharmaceutical industry to her new role.
• Her appointment is expected to provide continuity and stability in the company’s legal and compliance functions.